Avalon Globocare CORP 8-K filings

Change Agents Corporation announced the issuance of 1,550,000 shares of common stock under unregistered equity sales related to consulting agreements.

Change Agents Corporation has entered into a Business Loan and Security Agreement for $825,000, alongside a Confessed Judgment Secured Promissory Note, and issued shares in connection with a forbearance agreement.

Change Agents Corporation has entered into an Equity Purchase Agreement with Hudson Global Ventures, LLC, establishing a $10 million equity line of credit and issuing a warrant for 925,925 shares.

Avalon GloboCare Corp. has officially changed its name to Change Agents Corporation and will trade under the new ticker symbol CHGA, signaling a strategic shift towards agentic AI software solutions.

Avalon GloboCare Corp. announced a $400,000 financing through the sale of Series F Convertible Preferred Stock and common stock to an accredited investor.

Avalon GloboCare Corp. shareholders approved key proposals including a reverse stock split and a new 2026 incentive plan.

Avalon GloboCare issued $500,000 in promissory notes and announced key executive leadership changes.

Avalon GloboCare Corp. has filed pro forma financial information detailing the completed sale of its Avalon RT 9 Properties subsidiary to its Chairman for $9 million.

Avalon GloboCare's subsidiary, Avalon Quantum AI LLC, is collaborating with Amazon Web Services (AWS) and Caylent, Inc. to advance its agentic AI video platform, Catch-Up, with AWS providing $125,000 in funding.

Avalon GloboCare Corp. has been notified by Nasdaq of non-compliance with the minimum $1.00 bid price requirement.

Avalon GloboCare Corp. shareholders approved a proposal authorizing its Board to implement a future reverse stock split, though none is currently planned.

Avalon Globocare Corp. stockholders approved several critical proposals, including convertible note conversions, an equity exchange, and a potential reverse stock split.

Avalon GloboCare Corp. filed an amended 8-K to correct the number of shares issued from warrant exercises and provided further details on its recent $2.8 million private placement.

Avalon GloboCare Corp. announced the closing of a private placement raising $3.25 million upfront, with potential for an additional $6.5 million from warrant exercises, to fund operations and debt repayment.

Avalon GloboCare Corp. announced its subsidiary, Avalon Quantum AI LLC, has been accepted into the AMD AI Developer Program, gaining access to advanced AI development resources.

Avalon Globocare Corp. secured $207,000 in gross proceeds from a new promissory note and announced significant changes to its Board of Directors and committee assignments.

Avalon Globocare Corp. divests its principal office property to its Chairman for $9 million and extends payment deadlines on a $375,000 bridge note.

Avalon GloboCare Corp. announced the conversion of $2.6 million in debentures into common stock, significantly strengthening its balance sheet and improving capital structure.

Avalon GloboCare Corp. announced the mutual termination of its merger agreement with YOOV Group Holding Limited and its subsidiary filed a provisional patent for evidence-constrained AI video commentary.

Avalon GloboCare announced the renewal of FDA registration for its KetoAir breathalyzer and plans a B2B and B2C launch through its generative AI platform, Catch-Up, in Q2 2026.

Avalon GloboCare Corp. announced it has regained compliance with Nasdaq's minimum stockholders equity requirement and launched marketing for its generative AI video platform.

Avalon GloboCare Corp. announced the results of its annual stockholders meeting, where six directors were elected and M&K CPAS, PLLC was ratified as the independent auditor.

Avalon GloboCare's board director discusses the newly acquired RPM Interactive's generative AI video platform and its synergy with the KetoAir breathalyzer in a recent interview.

Avalon GloboCare Corp. has acquired generative AI software company RPM Interactive in an all-stock deal, which is expected to resolve its Nasdaq minimum stockholders equity deficiency.

Avalon GloboCare announced Q3 2025 progress for its KetoAir breathalyzer, including a first-responder health program and international expansion into the UK.

Avalon GloboCare Corp. received a delisting notice from Nasdaq due to continued non-compliance with minimum stockholders' equity requirements, but plans to request a hearing.

Avalon GloboCare provides an investor update on its pending merger with YOOV Group Holding Limited, highlighting YOOV's impressive preliminary unaudited financial results for fiscal year 2025.

Avalon GloboCare Corp. filed an amendment to clarify details of a $500,000 common stock sale, update promissory note terms, and revise preferred stock beneficial ownership limits.

Avalon GloboCare Corp. announced its plan to launch online sales of its KetoAir breathalyzer device and accessories in the United Kingdom starting September 1, 2025.

Avalon GloboCare Corp. issued 221,000 unregistered common shares to a noteholder upon partial conversion of an outstanding promissory note, increasing total shares outstanding to 3,690,109.